[go: up one dir, main page]

MX2017009998A - Biomarcadores para cancer pancreatico. - Google Patents

Biomarcadores para cancer pancreatico.

Info

Publication number
MX2017009998A
MX2017009998A MX2017009998A MX2017009998A MX2017009998A MX 2017009998 A MX2017009998 A MX 2017009998A MX 2017009998 A MX2017009998 A MX 2017009998A MX 2017009998 A MX2017009998 A MX 2017009998A MX 2017009998 A MX2017009998 A MX 2017009998A
Authority
MX
Mexico
Prior art keywords
biomarcators
pancreatico
cancer
diagnosis
present
Prior art date
Application number
MX2017009998A
Other languages
English (en)
Inventor
Crnogorac-Jurcevic Tatjana
RADON Tomasz
Original Assignee
Univ London Queen Mary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London Queen Mary filed Critical Univ London Queen Mary
Publication of MX2017009998A publication Critical patent/MX2017009998A/es

Links

Classifications

    • G01N33/57525—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G01N33/5758—
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Organic Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La presente invención se refiere a cánceres pancreáticos y el uso de biomarcadores en muestras biológicas para la diagnosis de estas afecciones, en particular adenocarcinoma ductal pancreático. El panel de biomarcadores comprende LYVE1, REG1 y TFF1. También se proporcionan métodos de tratamiento, así como kits útiles en la diagnosis y tratamiento de adenocarcinoma ductal pancreático. La presente invención es particularmente útil en el detectar PDAC de etapa temprana.
MX2017009998A 2015-02-05 2016-02-05 Biomarcadores para cancer pancreatico. MX2017009998A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1501930.0A GB201501930D0 (en) 2015-02-05 2015-02-05 Biomarkers for pancreatic cancer
PCT/GB2016/050277 WO2016124947A1 (en) 2015-02-05 2016-02-05 Biomarkers for pancreatic cancer

Publications (1)

Publication Number Publication Date
MX2017009998A true MX2017009998A (es) 2018-02-01

Family

ID=52746188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009998A MX2017009998A (es) 2015-02-05 2016-02-05 Biomarcadores para cancer pancreatico.

Country Status (15)

Country Link
US (3) US10782301B2 (es)
EP (2) EP4458849A3 (es)
JP (1) JP6786499B2 (es)
KR (1) KR102569984B1 (es)
CN (1) CN107533062B (es)
AU (1) AU2016214140B2 (es)
BR (1) BR112017016808A2 (es)
CA (1) CA2974775C (es)
CL (1) CL2017001972A1 (es)
GB (1) GB201501930D0 (es)
HK (1) HK1247276A1 (es)
IL (1) IL253710B (es)
MX (1) MX2017009998A (es)
SG (1) SG11201706223VA (es)
WO (1) WO2016124947A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10782301B2 (en) 2015-02-05 2020-09-22 Queen Mary University Of London Biomarkers for pancreatic cancer

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107102142A (zh) 2007-03-27 2017-08-29 伊缪诺维亚公司 检测腺癌的蛋白标志/标记
GB201517028D0 (en) * 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer
CN107674884A (zh) * 2017-09-05 2018-02-09 上海速创诊断产品有限公司 一种用于检测胰腺癌标记物reg1a的生物素化脂质体及其制备方法和应用
TWI643869B (zh) * 2017-12-14 2018-12-11 國立高雄大學 Molecular extension printing material and preparation method thereof, magnetic molecular extension printing material and preparation method thereof
US20210052231A1 (en) * 2017-12-14 2021-02-25 Salcit Technologies Private Limited Method and system for analyzing risk associated with respiratory sounds
KR102000387B1 (ko) * 2018-02-13 2019-07-15 서울대학교산학협력단 췌관내유두상점액종양의 악성도를 감별할 수 있는 단백질 바이오마커 및 그 용도
CN109358055A (zh) * 2018-12-18 2019-02-19 沈阳理工大学 增敏测定空气中氨的混合指示剂试纸及其制备和检测方法
CN111303281A (zh) * 2019-05-14 2020-06-19 长春恒晓生物科技有限责任公司 制备胰石蛋白抗体及建立检测psp方法
EP4045912A1 (en) * 2019-10-18 2022-08-24 Reccan Diagnostics AB Apparatuses and methods for detection of pancreatic cancer
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN113248609B (zh) * 2021-07-14 2021-09-10 深圳市盛波尔生命科学技术有限责任公司 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
CN115290732B (zh) * 2022-07-14 2025-02-25 西北大学 一种检测胰蛋白酶的电化学生物传感器及其制备方法
CN119724622B (zh) * 2024-11-25 2025-12-12 中国人民解放军总医院第五医学中心 一种评价ptt对胰腺癌治疗效果的方法、系统及设备

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
ES2320443T3 (es) 2002-09-30 2009-05-22 Oncotherapy Science, Inc. Genes y polipeptidos relacionados con canceres pancreaticos humanos.
AU2003900747A0 (en) 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
WO2004099432A2 (en) 2003-05-02 2004-11-18 The Johns Hopkins University Identification of biomarkers for detecting pancreatic cancer
WO2004102189A1 (en) 2003-05-15 2004-11-25 Europroteome Ag Biomarkers for the differential diagnosis of pancreatitis and pancreatic cancer
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
DE602006018578D1 (de) 2005-01-28 2011-01-13 Childrens Medical Center Diagnose- und prognoseverfahren von blasenkrebs.
US20070031867A1 (en) 2005-06-27 2007-02-08 John Wayne Cancer Institute Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome
US20070077582A1 (en) 2005-09-16 2007-04-05 Primera Biosystems, Inc. Method for quantitative detection of short RNA molecules
CA2635616A1 (en) 2006-01-05 2007-07-19 Carlo M. Croce Microrna expression abnormalities in pancreatic endocrine and acinar tumors
AU2007217861A1 (en) 2006-02-17 2007-08-30 Children's Medical Center Corporation Free NGAL as a biomarker for cancer
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
CA2664383C (en) 2006-09-19 2017-08-22 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
JP2010505847A (ja) * 2006-10-03 2010-02-25 ニューレン ファーマシューティカルズ リミテッド トレフォイル因子に結合する高次構造特異的抗体とこれを用いた癌および増殖障害の治療法
WO2008063479A2 (en) * 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
CA2685840C (en) 2007-04-30 2016-12-13 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
DK2294215T3 (da) 2008-05-12 2013-04-22 Genomic Health Inc Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
WO2009147530A2 (en) * 2008-06-06 2009-12-10 Neuren Pharmaceuticals Ltd Conformation specific antibodies that bind trefoil factors
JP2012100536A (ja) * 2009-03-02 2012-05-31 Genescience Co Ltd 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法
JP5786204B2 (ja) 2010-01-19 2015-09-30 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． インスリン様増殖因子ｉ型受容体（ｉｇｆ−１ｒ）を標的とする新規クラスの単一特異性ヒト化抗体および二重特異性ヒト化抗体
EP2415877A3 (en) * 2010-02-17 2012-02-15 Deutsches Krebsforschungszentrum Means and methods for diagnosing pancreatic cancer
WO2011137288A2 (en) 2010-04-30 2011-11-03 The Ohio State University Mirna networks in cancers and leukemias and uses thereof
WO2012100339A1 (en) 2011-01-27 2012-08-02 University Health Network Methods and compositions for the detection of pancreatic cancer
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
EP2758079A4 (en) * 2011-09-21 2015-05-13 Univ North Carolina PROCESS WITH BIOMARKERS FOR LIVER DISEASE
DE102012204366B4 (de) 2011-12-16 2017-07-27 Siemens Aktiengesellschaft Verfahren und Kit zur Identifizierung und Quantifizierung von einer einzelsträngigen Ziel-Nukleinsäure
US20150018235A1 (en) * 2012-01-13 2015-01-15 Oncocyte Corporation Methods and Compositions for the Treatment and Diagnosis of Pancreatic Cancer
US20150011414A1 (en) 2012-01-16 2015-01-08 Herlev Hospital Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
US20130216545A1 (en) * 2012-02-19 2013-08-22 Claresa Levetan Early Diagnosis and Novel Treatment of Cancer
WO2013152989A2 (en) 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
WO2014062856A1 (en) * 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US20140271621A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Methods of prognosis and diagnosis of pancreatic cancer
US20150018230A1 (en) 2013-06-11 2015-01-15 Indiana University Research And Technology Corp. PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA
GB201501930D0 (en) * 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
GB201517028D0 (en) 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10782301B2 (en) 2015-02-05 2020-09-22 Queen Mary University Of London Biomarkers for pancreatic cancer
US11977077B2 (en) 2015-02-05 2024-05-07 Queen Mary University Of London Biomarkers for pancreatic cancer

Also Published As

Publication number Publication date
BR112017016808A2 (pt) 2018-04-03
CA2974775C (en) 2023-11-07
US10782301B2 (en) 2020-09-22
SG11201706223VA (en) 2017-08-30
KR20170129118A (ko) 2017-11-24
AU2016214140B2 (en) 2021-11-04
CL2017001972A1 (es) 2018-03-23
KR102569984B1 (ko) 2023-08-22
US20190204323A1 (en) 2019-07-04
US20220042998A1 (en) 2022-02-10
CN107533062A (zh) 2018-01-02
CA2974775A1 (en) 2016-08-11
EP4458849A3 (en) 2024-12-04
HK1247276A1 (zh) 2018-09-21
AU2016214140A1 (en) 2017-08-17
IL253710B (en) 2020-08-31
US20250251399A1 (en) 2025-08-07
IL253710A0 (en) 2017-09-28
JP6786499B2 (ja) 2020-11-18
EP3254111A1 (en) 2017-12-13
JP2018504609A (ja) 2018-02-15
CN107533062B (zh) 2021-03-23
WO2016124947A1 (en) 2016-08-11
GB201501930D0 (en) 2015-03-25
EP4458849A2 (en) 2024-11-06
US11977077B2 (en) 2024-05-07

Similar Documents

Publication Publication Date Title
MX2017009998A (es) Biomarcadores para cancer pancreatico.
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX390772B (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
BR112013004673A8 (pt) biomarcadores e métodos de tratamento.
MX2020004567A (es) Metodos diagnosticos y terapeuticos para el cancer.
EP3606507A4 (en) SEROLOGICAL BIOMARKERS FOR EARLY DIAGNOSIS OF LUNG CANCER
MX2015011774A (es) Biomarcadores y metodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
MX340453B (es) Biomarcadores para cancer de pulmon.
MX365421B (es) Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.
WO2015171736A3 (en) Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
MX2016011377A (es) Metodo para diagnosticar cancer colorrectal a partir de una muestra de heces humanas por pcr cuantitativa, cebadores y equipo.
MX2013014153A (es) Biomarcadores paa terapia de inhibidor de hedgehog.
MX2016006125A (es) Procedimiento, matriz y uso de los mismos.
EP3907509A3 (en) Diagnosis of early stage pancreatic cancer
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
EP3894861C0 (en) DETECTION OF BIOMARKERS FOR NON-SMALL CELL LUNG CANCER
NZ729773A (en) Biomarkers for disease progression in melanoma
MX2015013993A (es) Procedimientos y series para su uso en los mismos.
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
ES2548299A1 (es) Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama
MX381238B (es) Isoformas delta133p53beta y delta133p53gamma son biomarcadores de células madre cancerosas.